{"product_id":"haemonetics-bcg-matrix","title":"Haemonetics Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalysis of Haemonetics' product portfolio using Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003ePrintable summary optimized for A4 and mobile PDFs, enabling efficient offline analysis of Haemonetics' portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eHaemonetics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Haemonetics BCG Matrix you're previewing mirrors the final purchase. It's a complete, ready-to-use report detailing market positions, growth rates, and strategic recommendations for your decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHaemonetics operates in a dynamic healthcare market. Their products likely fall into different growth and market share categories. A glimpse into their BCG Matrix reveals potential \"Stars\" like their blood management tech. This helps identify \"Cash Cows\" that generate steady revenue. Examining \"Dogs\" and \"Question Marks\" is crucial for strategic planning. \u003c\/p\u003e\n\u003cp\u003eDive deeper into Haemonetics' BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Business Unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Hospital business unit at Haemonetics is a star, driven by Interventional Technologies and Blood Management Technologies. This segment's growth is fueled by acquisitions like OpSens and Attune Medical. Haemonetics anticipates a robust reported revenue increase of 27% to 32% for fiscal year 2025. Organic revenue growth, excluding acquisitions, is projected at 13% to 16%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlasma Business Unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Plasma Business Unit is a Star within Haemonetics' BCG Matrix, contributing significantly to revenue. This unit focuses on solutions for blood component collection and separation, crucial for transfusion needs. Haemonetics aims to enhance donor safety, increase yields, and control costs. In fiscal year 2024, Haemonetics reported $1.2 billion in revenue, with the plasma business being a key driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexSys PCS System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe NexSys PCS system, featuring innovations like a new plasma collection bowl and Express Plus® technology, highlights Haemonetics' focus on plasma collection advancements. These improvements aim to boost efficiency. FDA clearances for these technologies are key. Haemonetics reported $298.9 million in plasma sales for Q2 2024, showing strong market performance. Continuous innovation and regulatory approvals are critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTEG 6s System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe TEG 6s system, now enhanced with the Global Hemostasis-HN assay cartridge, enhances Haemonetics' viscoelastic testing. FDA clearance for the new cartridge allows use in adult cardiovascular surgeries and liver transplants. This expansion bolsters its status as a star product. The TEG 6s system contributed significantly to Haemonetics' revenue in 2024. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eThe TEG 6s system is a key product for Haemonetics.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt improves patient care in critical situations.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe system's revenue increased by 15% in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt has a strong market position.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions (Attune Medical)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaemonetics' strategic acquisition of Attune Medical, including its ensoETM® device, strengthens its foothold in the electrophysiology sector. This move is designed to improve patient outcomes and boost operational efficiency. The ensoETM device is designed to minimize esophageal injuries during cardiac ablations.\u003c\/p\u003e\n\u003cp\u003eThe integration is expected to enhance Haemonetics' product portfolio. The acquisition of Attune Medical supports Haemonetics' commitment to innovation. This includes the ensoETM device, which has shown promise in reducing both procedure times and hospital readmissions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAttune Medical's ensoETM® device reduces esophageal injuries.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe acquisition supports Haemonetics' growth strategy.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIntegration aims to improve patient outcomes.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt also aims to improve operational efficiency.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Surge: Hospital \u0026amp; Plasma Units Lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaemonetics' Stars, including the Hospital and Plasma Business Units, drive significant revenue and growth. The Plasma Business Unit focuses on blood component solutions. Haemonetics' TEG 6s system saw a 15% revenue increase in 2024, showcasing its strong market position.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eBusiness Unit\u003c\/th\u003e\n\u003cth\u003eKey Products\/Services\u003c\/th\u003e\n\u003cth\u003e2024 Revenue (approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital\u003c\/td\u003e\n\u003ctd\u003eInterventional Tech, Blood Management\u003c\/td\u003e\n\u003ctd\u003ePart of overall growth, specific figures vary.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma\u003c\/td\u003e\n\u003ctd\u003eBlood Component Solutions\u003c\/td\u003e\n\u003ctd\u003e$1.2 billion (Annual)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTEG 6s\u003c\/td\u003e\n\u003ctd\u003eViscoelastic Testing System\u003c\/td\u003e\n\u003ctd\u003e15% revenue increase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Blood Component Collection (MCS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaemonetics' MCS automated blood collection systems are cash cows, crucial for Blood Center revenue. These systems compete with manual collection methods, especially for red cells. In 2024, the Blood Center segment contributed significantly to Haemonetics' revenue, demonstrating its importance. While growth might be slower than in other areas, the MCS maintains a stable cash flow. The systems provide a consistent, reliable income stream. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBloodTrack HaemoBank\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe BloodTrack HaemoBank system, a cash cow for Haemonetics, offers stable revenue. This software ensures efficient blood storage and management within hospitals. Its established presence, integrated into hospital systems, provides a reliable revenue stream. In fiscal year 2024, Haemonetics reported a steady revenue from its blood management solutions. This solution offers a low-growth potential due to market saturation and established position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTEG 5000 System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe TEG 5000 system, a cash cow in Haemonetics' portfolio, enjoys widespread approval across diverse markets. Its established market presence and broad application range ensures steady demand. In 2024, the TEG 5000 likely generated substantial, reliable revenue. This system remains a key revenue driver. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVascular Closure Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWithin Haemonetics' Interventional Technologies, vascular closure products are a reliable source of income. These products are crucial for sealing arterial and venous punctures following interventional procedures. Vascular closure products ensure a steady cash flow, although growth isn't rapid. This sector provides stability within the company's broader portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVascular closure products are vital for closing punctures after procedures.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThey offer a stable revenue stream within Interventional Technologies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis segment contributes to consistent cash flow.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGrowth is steady, not explosive.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemostasis Management Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaemonetics' hemostasis management products, a key part of their Blood Management Technologies, form a solid revenue base. These products are crucial for hospitals in managing bleeding and clotting during surgeries. This critical function ensures consistent demand and a steady cash flow. In 2024, the global hemostasis products market was valued at approximately $6.5 billion. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eRevenue stability from essential surgical products.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSupports steady cash flow due to reliable demand.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGlobal market size of $6.5 billion in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on managing bleeding and clotting.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemostasis Products: A $6.5B Revenue Stream!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash cows like hemostasis products ensure steady revenue. These products address critical hospital needs, supporting consistent demand. In 2024, the hemostasis market hit about $6.5 billion. This reliable income bolsters Haemonetics' financial stability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMarket Role\u003c\/th\u003e\n\u003cth\u003e2024 Revenue Contribution\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemostasis Products\u003c\/td\u003e\n\u003ctd\u003eSurgical bleeding control\u003c\/td\u003e\n\u003ctd\u003e$6.5 billion (Global Market)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMCS automated systems\u003c\/td\u003e\n\u003ctd\u003eBlood collection\u003c\/td\u003e\n\u003ctd\u003eSignificant Blood Center revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBloodTrack HaemoBank\u003c\/td\u003e\n\u003ctd\u003eBlood storage\u003c\/td\u003e\n\u003ctd\u003eSteady revenue stream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWhole Blood Collection (Transfusion Medicine Business)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaemonetics' whole blood collection business, classified as a 'dog,' was divested to GVS, S.p.A. The sale, finalized in 2024, reflects a strategic shift away from this area. This decision aligns with Haemonetics' focus on higher-growth markets. The whole blood segment showed limited profitability, prompting the strategic exit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Blood Center Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Blood Center segment of Haemonetics, excluding apheresis, struggles due to competition. Revenue declines, as seen in 2024 reports, indicate a 'dog' status. For example, in Q1 2024, Haemonetics reported a 5.6% decrease in this segment. Divesting or minimizing investment is needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManual Whole Blood Collection Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManual whole blood collection systems, part of Haemonetics' BCG matrix, are struggling. They face strong competition and declining market share. Automated systems are becoming more popular, which hurts manual methods. These systems are likely 'dogs' due to their poor growth. In 2024, the manual blood collection market saw a 7% decrease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts Facing Slower Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProducts with slow adoption rates, possibly due to partnership dependencies like those with the American Red Cross, often end up categorized as \"dogs\" in the BCG Matrix. These face challenges in market penetration and depend heavily on specific customer groups, limiting growth. Haemonetics' strategic decisions regarding these products are crucial, with options including revitalization or divestiture. For instance, if a product's sales growth is below the industry average, it could be a \"dog.\"\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSlow Adoption: Products face slow adoption.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket Penetration: Issues with market penetration.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic Reassessment: Requires strategic reassessment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDivestment: Divestiture could be the option.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts with High Competition and Price Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProducts in highly competitive markets, like certain blood management devices, can be classified as dogs. Intense price competition erodes profit margins, decreasing their overall appeal. Haemonetics, for example, faces pricing pressure in the plasma collection market. These products need careful monitoring to limit financial downsides and leverage any residual worth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePlasma collection market is highly competitive, with pricing pressure impacting profitability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProducts in this category may have lower profit margins.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on cost management and efficiency is crucial to minimize losses.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic decisions are needed to maximize value.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStruggling Segments: BCG Matrix Dogs Identified\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Haemonetics' BCG Matrix include struggling segments and products. These are often in competitive markets or face slow adoption. The manual blood collection market decreased by 7% in 2024. Strategic actions, such as divestiture, are typical.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\/Product\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWhole Blood Collection\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eDivested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood Center (Excl. Apheresis)\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eMinimize Investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual Whole Blood Systems\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eReview and adapt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensor Guided Technologies (Acquired from OpSens)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSensor Guided Technologies, acquired from OpSens, fall into the question mark category. The OpSens acquisition aimed to boost Haemonetics' hospital business. However, market acceptance and tech integration remain uncertain. Turning this into a star requires substantial investment and strategic marketing. In 2024, the deal value was approximately $49 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Plasma Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaemonetics' new plasma technology for the NexSys PCS system is a question mark in its BCG matrix. This technology, despite its high growth potential, currently has a low market share. For instance, Haemonetics' plasma sales in Q1 2024 were $169.4 million, a 3.5% increase, indicating growth, but market share specifics are not fully disclosed. The company must invest substantially to establish this technology as a standard in plasma collection centers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransfusion Management Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTransfusion Management Technologies, vital for hospitals, face high growth potential but low market share. To boost this, significant investments in technology are crucial. Without rapid market share gains, the product risks becoming a \"dog.\" Haemonetics' focus here requires strategic decisions. In 2024, the global blood transfusion market was valued at approximately $3.7 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew TEG 6s Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe TEG 6s, a question mark in Haemonetics' portfolio, targets expanded U.S. indications. This move demands substantial investment and regulatory approvals. Success could elevate TEG 6s, but failure risks limited market impact. In 2024, Haemonetics' total revenue was approximately $1.2 billion. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eU.S. regulatory hurdles present a challenge.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGlobal approvals offer a potential blueprint.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestment is crucial for indication expansion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket success hinges on broadened applications.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor Haemonetics, expanding into emerging markets is a question mark in the BCG Matrix. These markets offer substantial growth potential, but also come with considerable risks. Regulatory challenges, intense competition, and difficulties in market access can hinder success. Strategic investments and customized strategies are critical to capturing opportunities and becoming a market leader in these regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMarket entry requires careful planning and resource allocation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCompetition from both global and local players is a key factor.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRegulatory compliance and navigating local healthcare systems are essential.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSuccess depends on adapting products and strategies to local needs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNavigating Growth: Strategic Moves in Blood Transfusion Tech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion marks, as seen in Haemonetics' BCG matrix, include Sensor Guided Technologies and new plasma technology. These face high growth potential but low market share, demanding significant investment to succeed. Strategic focus is vital for these products to avoid becoming \"dogs\". The global blood transfusion market, important for some of these technologies, was about $3.7 billion in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Category\u003c\/th\u003e\n\u003cth\u003eChallenge\u003c\/th\u003e\n\u003cth\u003eStrategic Need\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor Guided Technologies\u003c\/td\u003e\n\u003ctd\u003eMarket acceptance\u003c\/td\u003e\n\u003ctd\u003eInvestment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Plasma Tech\u003c\/td\u003e\n\u003ctd\u003eLow market share\u003c\/td\u003e\n\u003ctd\u003eEstablishment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransfusion Tech\u003c\/td\u003e\n\u003ctd\u003eMarket share gains\u003c\/td\u003e\n\u003ctd\u003eInvestments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eOur BCG Matrix is constructed using Haemonetics' financial data, industry reports, and market analyses for comprehensive and strategic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070127485312,"sku":"haemonetics-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/haemonetics-bcg-matrix.png?v=1749412597","url":"https:\/\/swotanalysistemplates.com\/products\/haemonetics-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}